Sorrento Therapeutics Inc. buy yester
Start price
02.11.20
/
100%
€6.15
Target price
04.11.21
€13.00
Performance (%)
-4.96%
End price
05.11.21
€5.85
Summary
This prediction ended on 05.11.21 with a price of €5.85. With a performance of -4.96%, the BUY prediction by yester finished with a loss. yester has 100% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Sorrento Therapeutics Inc. | - | - | - | - |
iShares Core DAX® | -0.870% | -1.700% | 10.560% | 13.129% |
iShares Nasdaq 100 | -5.561% | -3.604% | 34.335% | 39.856% |
iShares Nikkei 225® | -6.138% | -7.732% | 16.215% | 0.044% |
iShares S&P 500 | -3.141% | -2.011% | 24.534% | 39.859% |
According to yester what are the pros and cons of Sorrento Therapeutics Inc. for the foreseeable future?
Pros
Could be very worthwhile Investment >20% year
Very Future proof/growth oriented business model
Top 10 in its market
Leading role in innovation
Cons
Comments by yester for this prediction
In the thread Sorrento Therapeutics Inc. diskutieren
Buy mit Kursziel 11,0
Kursziel geändert auf 15,0
Kursziel geändert auf 10,0
Kursziel geändert auf 13,0
In the thread Trading Sorrento Therapeutics Inc.
Die von yester gewählte maximale Laufzeit wurde überschritten
Stopped prediction by yester for Sorrento Therapeutics Inc.
Sorrento Therapeutics Inc.
Start price
Target price
Perf. (%)
€6.20
02.11.20
02.11.20
€5.00
02.11.20
02.11.20
-0.74%
02.11.20
02.11.20
Could be very worthwhile Investment >20% year
Very Future proof/growth oriented business model
Top 10 in its market
Leading role in innovation
Sorrento Therapeutics Inc.
Start price
Target price
Perf. (%)
€8.17
21.09.20
21.09.20
€12.00
02.11.20
02.11.20
-24.15%
02.11.20
02.11.20
Could be very worthwhile Investment >20% year
Very Future proof/growth oriented business model
Top 10 in its market
Leading role in innovation
Sorrento Therapeutics Inc.
Start price
Target price
Perf. (%)
€5.60
08.09.20
08.09.20
€7.00
21.09.20
21.09.20
46.07%
21.09.20
21.09.20
Could be very worthwhile Investment >20% year
Very Future proof/growth oriented business model
Top 10 in its market
Leading role in innovation